EUVIMEDEUVIMED entdecken
Crossref

Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment

Burak Kuzu iD, Derya Osmaniye iD, Abdullah Burak Karaduman, Yusuf Özkay iD

Archiv der Pharmazie · 2025-10 · 358 (10)

DOI: 10.1002/ardp.70122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 13.10.2025. Verfasst von Burak Kuzu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Van Yuzuncu Yil University, Van, Türkiye. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Pyrazoles, Antineoplastic Agents, Oxadiazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new series of pyrazole–thiazole–oxadiazole hybrid compounds targeting the EGFR and VEGFR2 enzymes was designed and synthesized using innovative approaches. The compounds were characterized through spectral methods, and their cytotoxic activities were evaluated against the A549 lung and HT‐29 colon cancer cell line using the MTT assay. Among them, compounds 17i and 17m exhibited notable cytotoxicity, with 17i demonstrating approximately threefold greater activity compared to the reference drug sorafenib for A549 cells. Flow cytometry analysis revealed that 17i induced extensive necrotic cell death, while 17m triggered a more targeted and controlled apoptotic mechanism. In vitro enzyme inhibition assays demonstrated that 17i inhibited EGFR and VEGFR2 with IC 50 values of 0.158 and 0.128 µM, respectively. In contrast, 17m exhibited more potent inhibition of EGFR (IC 50 = 0.012 µM) and moderate activity against VEGFR2 (IC 50 = 0.309 µM). Molecular docking and molecular dynamics simulations further supported the structural stability of the complexes formed by these compounds with their target enzymes, highlighting their potential as effective enzyme inhibitors. Collectively, these findings suggest that pyrazole–thiazole–oxadiazole hybrids represent promising candidates for targeted cancer therapy at the cellular level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2PyrazolesAntineoplastic AgentsOxadiazolesThiazolesProtein Kinase InhibitorsHumansErbB ReceptorsStructure-Activity RelationshipMolecular Docking SimulationDrug Screening Assays, AntitumorDose-Response Relationship, DrugMolecular StructureCell ProliferationApoptosisA549 CellsHT29 CellsMolecular Dynamics SimulationCell Line, Tumor

Stichwörter der Autor:innen

EGFR/VEGFR2SARcytotoxicityhybridization

Substanzen

ErbB ReceptorsVascular Endothelial Growth Factor Receptor-2PyrazolesAntineoplastic AgentsOxadiazolesEGFR protein, humanKDR protein, humanThiazolesProtein Kinase Inhibitorspyrazole

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Van Yuzuncu Yil University, Van, Türkiye.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
  • Central Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
  • Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.

ORCID-Profile: Burak Kuzu, Derya Osmaniye, Yusuf Özkay

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Kuzu, B., Osmaniye, D., Karaduman, A. B., & Özkay, Y. (2025). Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment. Archiv der Pharmazie, 358(10). https://doi.org/10.1002/ardp.70122

Vancouver

Kuzu B, Osmaniye D, Karaduman AB, Özkay Y. Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment. Archiv der Pharmazie. 2025;358(10). doi:10.1002/ardp.70122

BibTeX
@article{Kuzu2025,
  author = {Kuzu, Burak and Osmaniye, Derya and Karaduman, Abdullah Burak and Özkay, Yusuf},
  title = {Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {10},
  doi = {10.1002/ardp.70122}
}
Kostenlos starten →